| CCNU | Pegylated liposomal doxorubicin | VDC-1101 and prednisone | Masitinib |
---|
References | N | CR (N, %) | N | CR (N, %) | N | CR (N, %) | N | CR (N, %) |
---|
Morges, 2014 [4] | | | | | 10 | 0 (0%) | | |
Risbon, 2006 [2] | 46a
| 15 (33%) | | | | | | |
Williams, 2006 [3] | 36 | 6b (33%) | | | | | | |
Graham, 1999 [6] | 5 | 5c (100%) | | | | | | |
Vail, 1997 [5] | | | 9 | 3 (33%) | | | | |
Holtermann, 2016 [7] | | | | | | | 10d
| 2 (20%) |
TOTAL
| 87 | 26 (30%) | 9 | 3 (33%) | 10 | 0 (0%) | 1- | 2 (20%) |
-
Abbreviations: CR complete remission, N number of dogs
-
a14 dogs received CCNU monotherapy, 27 also received glucocorticoids that were later either tapered, discontinued or maintained. The co-administration of prednisone was reported not to be significantly associated with the response or its duration. Other concurrent medications included PEG L-asparaginase (6 dogs), essential fatty acids (8), nonsteroidal anti-inflammatory drugs (3), retinoids (2), and interferon (1)
-
b67% of the dogs experiencing a CR also received concurrent glucocorticoids
-
c2 dogs may have received concurrent surgery
-
dthe response was assessed on the three most dominant “target” lesions